These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2177576)

  • 1. The receptor for human urokinase: a potential target for anti-invasive and anti-metastatic therapy.
    Masucci MT; Blasi F
    Thromb Res Suppl; 1990; 11():49-60. PubMed ID: 2177576
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
    Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin.
    Ellis V; Danø K
    Biochem J; 1993 Dec; 296 ( Pt 2)(Pt 2):505-10. PubMed ID: 8257443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
    Albo D; Berger DH; Rothman VL; Tuszynski GP
    J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    Hudson MA; McReynolds LM
    J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
    Engelholm LH; Behrendt N
    Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to comment on 'Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system' (A. A-R. Higazi).
    Behrendt N; Danø K
    FEBS Lett; 1997 Feb; 402(2-3):293-4. PubMed ID: 9037213
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
    Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
    Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on: 'Effect of purified soluble urokinase receptor on the plasminogen prourokinase activation system' by N. Behrendt and K. Dano, FEBS Letters, 393 (1996) 31-36.
    Higazi AA
    FEBS Lett; 1997 Feb; 402(2-3):291-2. PubMed ID: 9037212
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator.
    Solberg H; Løber D; Eriksen J; Ploug M; Rønne E; Behrendt N; Danø K; Høyer-Hansen G
    Eur J Biochem; 1992 Apr; 205(2):451-8. PubMed ID: 1374026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urokinase receptor and regulation of cell surface plasminogen activation.
    Blasi F; Behrendt N; Cubellis MV; Ellis V; Lund LR; Masucci MT; Møller LB; Olson DP; Pedersen N; Ploug M
    Cell Differ Dev; 1990 Dec; 32(3):247-53. PubMed ID: 1965953
    [No Abstract]   [Full Text] [Related]  

  • 14. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
    Ellis V; Pyke C; Eriksen J; Solberg H; Danø K
    Ann N Y Acad Sci; 1992 Dec; 667():13-31. PubMed ID: 1339241
    [No Abstract]   [Full Text] [Related]  

  • 15. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
    Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
    J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both pro-uPA and uPA: PAI-1 complex bind to the alpha 2-macroglobulin receptor/LDL receptor-related protein. Evidence for multiple independent contacts between the ligands and receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Gliemann J; Andreasen PA
    Ann N Y Acad Sci; 1994 Sep; 737():483-5. PubMed ID: 7944152
    [No Abstract]   [Full Text] [Related]  

  • 18. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
    Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
    Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
    Reuning U; Bang NU
    Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.
    Wilhelm O; Weidle U; Höhl S; Rettenberger P; Schmitt M; Graeff H
    FEBS Lett; 1994 Jan; 337(2):131-4. PubMed ID: 8287966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.